Unaudited Financial Results for the Half Year Ended on 30th September, 2025

Revenue Growth 20pctPat Growth 25pctEbitda Margin CompressionNegative Operating CashflowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.0%Reaction day

₹64.15

prior close

₹67.35

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.9%+4.1% vs market

Pharmaceuticals peers, median of 157sector+0.8%+4.2% vs sector

On the reaction day the stock moved 4.1 pts more than Nifty Microcap 250 and 4.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.0+0.9+4.1+0.8+4.2

Next day

-0.2+0.8-1.1+0.5-0.7

-5.2+0.7-6.0+0.4-5.6

-7.7+1.3-9.1+0.6-8.3

-9.0+0.5-9.5-0.1-8.9

-8.7+0.4-9.0-0.6-8.1

+0.1-1.5+1.6-1.2+1.3

15d

-2.8-2.4-0.4-1.8-1.0

-2.1-4.4+2.3-2.6+0.5

+38.4-7.2+45.7-5.4+43.8

+47.8-5.0+52.8-6.0+53.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aptus Pharma reported strong H1 FY26 results with revenue from operations of Rs. 1,437.75 lakhs, up 47.38% from Rs. 975.57 lakhs in H1 FY25. EBITDA grew 36.12% to Rs. 294.55 lakhs, though EBITDA margin compressed by 169 basis points to 20.49%. Profit After Tax (PAT) rose 33.81% to Rs. 174.69 lakhs, with PAT margin at 12.15% versus 13.38% previously. The company has fully utilized its IPO proceeds of Rs. 1,302 lakhs towards capital expenditure, working capital, and general corporate purposes. The statutory auditors issued an unqualified limited review report with no qualifications.

Likely market impact

Strong top-line and bottom-line growth should be viewed positively by shareholders, though the slight margin compression signals rising costs. The post-IPO growth track record is encouraging, but watch for any further margin pressure in upcoming quarters.